OncoMatch/Clinical Trials/NCT06252649
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Is NCT06252649 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including FOLFIRI Regimen and Sotorasib for metastatic colorectal cancer.
Treatment: FOLFIRI Regimen · Sotorasib · Panitumumab · Bevacizumab-awwb — The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS p.g12c mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: KRAS inhibitor
Previous treatment with a KRAS p.G12C inhibitor
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ironwood Cancer and Research Centers Scottsdale · Chandler, Arizona
- Providence Saint Jude Medical Center · Fullerton, California
- City of Hope National Medical Center · Long Beach, California
- Cancer and Blood Research Center, LLC · Los Alamitos, California
- California Research Institute · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify